Treatment With Namenda in Women at Risk for Cognitive Decline
Completed · Not applicable
Conditions studied: Dementia
In brief
This research aims to explore the effectiveness of memantine (Namenda) in treating post-menopausal women between the ages of 50 and 65, who are at risk for cognitive decline. Memantine has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
Key facts
- Study ID
- NCT00242632
- Run by
- Stanford University
- People needed
- 22
- Starts
- 2004-06-01
- Expected to finish
- 2009-12-01
- Last updated by the study team
- 2017-06-14
Who can join
Age: 50 and older, up to 65. Sex: female. Healthy volunteers: accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.